70,213 Shares in Insulet Co. (NASDAQ:PODD) Acquired by Caisse DE Depot ET Placement DU Quebec

Caisse DE Depot ET Placement DU Quebec acquired a new stake in Insulet Co. (NASDAQ:PODD - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 70,213 shares of the medical instruments supplier's stock, valued at approximately $16,342,000. Caisse DE Depot ET Placement DU Quebec owned 0.10% of Insulet at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Blue Trust Inc. boosted its holdings in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 58 shares during the period. Venturi Wealth Management LLC lifted its position in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 133 shares during the period. International Assets Investment Management LLC bought a new stake in Insulet during the second quarter worth about $32,000. UMB Bank n.a. raised its position in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock valued at $37,000 after buying an additional 81 shares in the last quarter. Finally, CVA Family Office LLC boosted its position in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock worth $50,000 after acquiring an additional 145 shares in the last quarter.

Insulet Stock Performance

Shares of Insulet stock traded down $0.29 during mid-day trading on Monday, hitting $266.49. 609,741 shares of the stock were exchanged, compared to its average volume of 769,367. The company has a 50-day simple moving average of $244.40 and a 200 day simple moving average of $214.37. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The company has a market capitalization of $18.69 billion, a P/E ratio of 45.68, a P/E/G ratio of 4.08 and a beta of 1.22.

Wall Street Analysts Forecast Growth

PODD has been the subject of several recent analyst reports. Citigroup upped their price objective on Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a research report on Tuesday, October 1st. Barclays raised their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a report on Monday, November 11th. Sanford C. Bernstein started coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an "outperform" rating and a $300.00 price target for the company. Raymond James raised their target price on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a research report on Monday, October 14th. Finally, UBS Group boosted their price target on shares of Insulet from $211.00 to $223.00 and gave the stock a "neutral" rating in a research report on Friday, August 9th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.